Positions

Overview

  • CF researcher

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 CFTR dysfunction increases endoglin and TGF-β signaling in airway epithelia 2019
    2019 Objective versus self-reported adherence to airway clearance therapy in cystic fibrosis 2019
    2019 An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB) 2019
    2019 Reply to Finotti et al. 2019
    2018 MicroRNA-145 antagonism reverses TGF-b inhibition of F508del CFTR correction in airway Epithelia 2018
    2017 Airway microbiota across age and disease spectrum in cystic fibrosis. 2017
    2017 Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: Analysis of oxidative stress in lung fibroblasts 2017
    2017 Effect of prenatal versus postnatal Vitamin D deficiency on pulmonary structure and function in mice 2017
    2016 Constrictive bronchiolitis in cystic fibrosis adolescents with refractory pulmonary decline 2016
    2016 Risk stratification model to detect early pulmonary disease in infants with cystic fibrosis diagnosed by newborn screening 2016
    2016 Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-years with cystic fibrosis and a CFTR gating mutation (KIWI): An open-label, single-arm study 2016
    2016 Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor 2016
    2015 Adherence to airway clearance therapy in pediatric cystic fibrosis: Socioeconomic factors and respiratory outcomes 2015
    2015 Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis 2015
    2015 Acute Kidney Injury in Hospitalized Children With Cystic Fibrosis 2015
    2014 TGF-beta downregulation of distinct chloride channels in cystic fibrosis-affected epithelia 2014
    2014 Development and maintenance of a biospecimen repository for clinical samples derived from pulmonary patients 2014
    2013 Erratum: Myofibroblast differentiation and enhanced Tgf-B signaling in cystic fibrosis lung disease (PLoS ONE (2013) 8 (8)) 2013
    2013 IP-10 Is a Potential Biomarker of Cystic Fibrosis Acute Pulmonary Exacerbations 2013
    2013 Myofibroblast Differentiation and Enhanced Tgf-B Signaling in Cystic Fibrosis Lung Disease 2013
    2013 Crohn's disease with pulmonary manifestations in children: 2 case reports and review of the literature 2013
    2011 Plasma TGF-β1 in pediatric cystic fibrosis: Potential biomarker of lung disease and response to therapy 2011
    2010 Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas 2010
    2009 Transforming growth factor-β1 in bronchoalveolar lavage fluid from children with cystic fibrosis 2009
    2009 Experience of the school-aged child with tracheostomy 2009
    2009 Association of lower airway inflammation with physiologic findings in young children with cystic fibrosis 2009
    2006 Physiologic, bronchoscopic, and bronchoalveolar lavage fluid findings in young children with recurrent wheeze and cough 2006

    Research Overview

  • Cystic Fibrosis, Pediatric Lung Disease, TGF-beta signaling, Airway Remodeling, miRNA

    • Principal Investigator On

  • Oligotherapeutics to Enhance CFTR Correction  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2019 - 2021
  • Overcoming Barriers to F508del CFTR Correction  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2017 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2019
  • Losartan as Anti-Inflammatory Therapy to Augment F508del CFTR Recovery  awarded by University of Miami 2017 - 2019
  • MiR-145 Mediated TGF-Beta Pathobiology in CF  awarded by Cystic Fibrosis Foundation 2017 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2017
  • Private Grant  awarded by Gilead Sciences 2015 - 2017
  • Mechanisms of Pulmonary Fibrosis in CF Lung Disease  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE 2015 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2016
  • Effect of Vitamin D Deficiency on Murine Lung Development and Function  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE 2013 - 2015
  • Myofibroblast Differentiation in Cystic Fibrosis  awarded by Cystic Fibrosis Foundation 2012 - 2015
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2013
  • Bronchoalveolar Lavage Fluid (BALF) Specimen Bank and Lower Airway Microbiome Analysis in Children and Adults With and Without Cystic Fibrosis (CF)  awarded by University of Colorado 2011 - 2013
  • Myofibroblast Proliferation in Cystic Fibrosis: A Novel Mechanism of Disease Modification  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE 2010 - 2012

    • Investigator On

  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation 2019 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2020
  • UAB Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation 2018 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2018
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation 2017 - 2018
  • Prevalence and Significance of Staphylococcus Aureus Small–Colony Variants  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2014 - 2018
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation 2016 - 2017
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2017
  • UAB Therapeutic Development Network Center  awarded by Cystic Fibrosis Foundation 2015 - 2016
  • Private Grant  awarded by PROQR THERAPEUTICS 2015 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2016
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation 2015 - 2016
  • The Genetic Contribution to Drug Induced Renal lnjury:The Drug Induced Renal Injury Consortium (DIRECT)  awarded by INTERNATIONAL SAE CONSORTIOUM, LTD 2013 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2015
  • UAB Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation 2014 - 2015
  • Translational Therapeutic Development Center  awarded by Cystic Fibrosis Foundation 2013 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2014
  • UAB Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation 2013 - 2014
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC 2013 - 2014
  • Private Grant  awarded by GRIFOLS, INC 2012 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2014
  • Pediatric Physician Training in Translational Research  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2008 - 2013
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC 2013

    • Education And Training

  • Johns Hopkins Hospital, Residency 2003
  • University of North Carolina Hospital, Postdoctoral Fellowship 2007

    • Full Name

  • William Harris